Capricor Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.13 | -$0.10 | -$0.11 |
| Q2 2024 | 1 | -$0.40 | -$0.32 | -$0.36 |
| Q3 2024 | 1 | -$0.40 | -$0.33 | -$0.36 |
| Q4 2024 | 4 | -$0.20 | -$0.16 | -$0.18 |
| Q1 2025 | 2 | -$0.40 | -$0.31 | -$0.36 |
| Q2 2025 | 1 | -$0.44 | -$0.36 | -$0.39 |
| Q3 2025 | 1 | -$0.43 | -$0.35 | -$0.39 |
| Q4 2025 | 1 | -$0.35 | -$0.29 | -$0.32 |
Capricor Therapeutics, Inc. Earnings Date And Information
Capricor Therapeutics, Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $-0.35 earnings per share for the quarter, missing analysts' consensus estimates of $-0.32 by $0.03. The company had revenue of 2.26 B for the quarter and had revenue of 25.18 M for the year. Capricor Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.83 diluted earnings per share) and currently has a price-to-earnings ratio of -0.05. Capricor Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Capricor Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$379.47 | $4.28 M | $2.26 B | ||
| 08/08/2024 | Q2 2024 | -$0.35 | $4.58 M | $3.97 M | ||
| 05/14/2024 | Q1 2024 | -$0.31 | $4.91 M | |||
| 03/11/2024 | Q4 2023 | -$0.02 | $12.09 M | |||
| 11/14/2023 | Q3 2023 | -$0.27 | -$0.25 | 0.02 | $3.15 M | $6.19 M |
| 08/08/2023 | Q2 2023 | -$0.29 | $3.00 M | $3.92 M | ||
| 05/12/2023 | Q1 2023 | $16.19 | $2.99 M | |||
| 03/17/2023 | Q4 2022 | -$0.31 | $957,351 | |||
| 11/10/2022 | Q3 2022 | -$0.28 | -$0.26 | 0.02 | $420,000 | $1.59 M |
| 08/11/2022 | Q2 2022 | -$0.28 | $390,000 | $0 | ||
| 05/11/2022 | Q1 2022 | -$0.32 | $0 | |||
| 03/10/2022 | Q4 2021 | -$0.26 | $244.65 M | |||
| 11/10/2021 | Q3 2021 | -$0.17 | $210,000 | $0 | ||
| 08/13/2021 | Q2 2021 | -$0.21 | $210,000 | $204,082 | ||
| 05/14/2021 | Q1 2021 | -$0.23 | $40,816 | |||
| 03/15/2021 | Q4 2020 | -$0.21 | $57,830 | |||
| 11/13/2020 | Q3 2020 | -$0.20 | $210,000 | $16,863 | ||
| 08/10/2020 | Q2 2020 | -$0.23 | $210,000 | $49,864 | ||
| 05/15/2020 | Q1 2020 | -$0.30 | $185,693 | |||
| 03/27/2020 | Q4 2019 | -$0.34 | $222,100 |
Capricor Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Capricor Therapeutics, Inc.'s earnings date?
Capricor Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
How can I listen to Capricor Therapeutics, Inc.'s earnings conference call?
The conference call for Capricor Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Capricor Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Capricor Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Capricor Therapeutics, Inc. generate each year?
Capricor Therapeutics, Inc. (:CAPR) has a recorded annual revenue of $25.18 M.
-
How much profit does Capricor Therapeutics, Inc. generate each year?
Capricor Therapeutics, Inc. (:CAPR) has a recorded net income of $25.18 M. Capricor Therapeutics, Inc. has generated $-0.83 earnings per share over the last four quarters.
-
What is Capricor Therapeutics, Inc.'s price-to-earnings ratio?
Capricor Therapeutics, Inc. (:CAPR) has a price-to-earnings ratio of -0.05 and price/earnings-to-growth ratio is 0.
